Dishman Pharma Q1 net dips 98% on standalone basis

Net sales dip by 14% to Rs 90 cr

Dishman Pharmaceuticals and Chemicals has posted a 98 per cent drop in its net profit for the quarter ended June 30, 2013 to Rs 8.95 lakh from Rs 6.97 crore in the corresponding quarter last fiscal on a standalone basis.

The net sales during the quarter dipped by 14 per cent on a year-on-year basis to Rs 89.85 crore from Rs 104.32 crore in Q1FY13.

On a consolidated basis, however, the net profit has dipped 24 per cent to Rs 29.24 crore during the first quarter of the current fiscal.

Net sales has fallen from Rs 315.27 crore to Rs 306.24 crore, a drop of around 3 per cent.

As far as segment performances go, on a standalone basis, the contract research and manufacturing services (CRAMS) vertical has seen a dip of 11 per cent to Rs 54.6 crore during the quarter under review, while income from other segments have fallen by 18 per cent to Rs 35.26 crore.

On a consolidated basis, the income from the CRAMS segment has actually grown from Rs 197 crore last fiscal to Rs 214 crore this year.

Income from other segments, however, have dipped by around 22 per cent to Rs 92.23 crore.